Almost all currently available treatments for inflammatory bowel disease (IBD) act by
inhibiting inflammation, often blocking specific inflammatory molecules. However, given the …

Background Knowledge of the real-world effectiveness and safety of tofacitinib for ulcerative
colitis (UC) is relevant to confirm the benefit observed in clinical trials. Methods This …

Background A treat-to-target strategy, in which strictly defined treatment targets facilitate
decision making in clinical practice, is advocated as an optimised management approach for …

Background Mirikizumab is a humanized monoclonal antibody targeting interleukin 23p19
with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and …

Endoscopic evaluation to reliably grade disease activity, detect complications including
cancer and verification of mucosal healing are paramount in the care of patients with …

Im Jahr 2019 wurden etwa 25 500 Patient* innen mit M. Crohn im Krankenhaus stationär
behandelt [1]. Meistens tritt die Erkrankung in der Adoleszenz und im jungen …

The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the
clinical and endoscopic remission of disease, reduce the incidence of complications such as …

Ulcerative colitis (UC) is one type of inflammatory bowel disease (IBD) and lactoferrin (LF) is
a promising protein drug to treat UC. However, targeted LF delivery to optimize …

Short-and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during
the last decade, shifting from symptom control to endoscopic healing and patient-centered …

Early diagnosis and the optimal control of inflammation, with a continuous cycle of
assessment, treatment, monitoring, and adjustment of therapy, is best practice for the …